<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895449</url>
  </required_header>
  <id_info>
    <org_study_id>UKE-SARS-CoV-2-ST</org_study_id>
    <nct_id>NCT04895449</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19</brief_title>
  <acronym>MVA-SARS2-ST</acronym>
  <official_title>A Multi-center, Randomized Controlled, Phase Ib/IIa Trial to Assess the Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Center for Infection Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IDT Biologika</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trial Center North (CTC North GmbH &amp; Co. KG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, randomized-controlled phase Ib/IIa study with an open-label run-in phase and an&#xD;
      open-label exploratory study arm to evaluate previously SARS-CoV-2-infected/vaccinated&#xD;
      individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized&#xD;
      SARS-CoV-2 spike protein (S).&#xD;
&#xD;
      This will be a phase Ib/IIa, multi-center study in approximately 240 adults aged 18 years and&#xD;
      older.&#xD;
&#xD;
      Study starts with an open-label run-in phase of three dose levels (Part A):&#xD;
&#xD;
        -  low dose ≥ 1 x 107 IU (N=10)&#xD;
&#xD;
        -  middle dose ≥ 5 x 107 IU (N=10)&#xD;
&#xD;
        -  high dose ≥ 1 x 108 IU (N=10)&#xD;
&#xD;
      Part B: Multi-center, open-label study. Participants with previous SARS-CoV-2 infection or&#xD;
      vaccination against SARS-CoV-2 will be recruited at 2 to 5 study sites in Germany and will&#xD;
      receive one dose of MVA-SARS-2-ST. Participants will be recruited at 2 to 5 study sites in&#xD;
      Germany. Participants will be randomized to one of the following cohorts (ratio 2:2:1)&#xD;
&#xD;
        -  low or middle dose on day 0, 28 (N = 60)&#xD;
&#xD;
        -  middle or high dose on day 0, 28 (N = 60)&#xD;
&#xD;
        -  Licensed COVID-19 Vaccine on day 0, day 28 (N = 30) Each participant will receive two&#xD;
           single injections, 28 days apart. All participants will be followed up for safety until&#xD;
           D168.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blinded (Phase IIa, Part A) with an open-label run-in Phase (Phase Ib) and an open-label Part (Phase IIa, Part B)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol</measure>
    <time_frame>during the entire study (up to 6 months)</time_frame>
    <description>Safety and reactogenicity will be assessed by observation, questionaire and diary. Occurence of Serious Adverse Events (SAE) will be collected throughout the entire study duration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who seroconverted</measure>
    <time_frame>during the entire study (up to 6 months)</time_frame>
    <description>Magnitude of SARS-CoV-2-S specific antibody responses will be measured by ELISA and neutralization assays</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>≥ 1 x 10E7 IU (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>≥ 1 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 &amp; 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>≥ 5 x 10E7 IU (middle dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>≥ 5 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 &amp; 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>≥ 1 x 10E8 IU (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>≥ 1 x 10E8 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 &amp; 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COVID-19 Vaccine on day 0, and placebo on day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-SARS-2-ST</intervention_name>
    <description>i.m. vaccine administration</description>
    <arm_group_label>≥ 1 x 10E7 IU (low dose)</arm_group_label>
    <arm_group_label>≥ 1 x 10E8 IU (high dose)</arm_group_label>
    <arm_group_label>≥ 5 x 10E7 IU (middle dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed COVID-19 vaccine</intervention_name>
    <description>i.m. vaccine administration</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent.&#xD;
&#xD;
          2. Healthy male and female adults aged 18 - 64 at time of informed consent (phase Ib&#xD;
             only).&#xD;
&#xD;
          3. Male and female adults aged 18 and above (phase IIa) at time of informed consent.&#xD;
&#xD;
          4. Phase IIa: Either in good or stable health in the opinion of the investigator.&#xD;
             Participants may have underlying illness as long as their symptoms are medically&#xD;
             controlled, and they are on a stable medication for the respective underlying illness&#xD;
             for at least 8 weeks before screening and no changes are expected dur-ing the study.&#xD;
&#xD;
          5. Body mass index 18.5 - 32.0 kg/m2 and weight &gt; 50 kg at screening.&#xD;
&#xD;
          6. Female participants: non-pregnant, non-lactating with negative pregnancy test.&#xD;
&#xD;
          7. Females who agree to comply with the applicable contraceptive requirements of the&#xD;
             protocol.&#xD;
&#xD;
          8. Documented previous SARS-CoV-2 infection (PCR-positive) OR documented vaccination&#xD;
             against SARS-CoV-2 with (conditionally) licensed vaccine against COVID-19, at least 6&#xD;
             months prior to in-clusion into this study. (phase IIa open-label only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live&#xD;
             vaccines) to 6 weeks after each trial vaccination.&#xD;
&#xD;
          2. Previous rMVA immunization.&#xD;
&#xD;
          3. Previous immunization with investigational vaccine against COVID-19.&#xD;
&#xD;
          4. Previous immunization with EUA/conditionally licensed vaccine against COVID-19 (not&#xD;
             applicable to phase IIa open-label exploratory study).&#xD;
&#xD;
          5. Evidence of active SARS-CoV-2 infection&#xD;
&#xD;
          6. Known allergy to the components of the MVA-SARS-2-ST vaccine product or history of&#xD;
             life-threatening reactions to vaccine containing the same substances.&#xD;
&#xD;
          7. Known allergy to the components of the comparator vaccine (phase IIa Part A).&#xD;
&#xD;
          8. Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by&#xD;
             any component of the trial vaccines.&#xD;
&#xD;
          9. Evidence in the participant's medical history or in the medical examination that might&#xD;
             influence either the safety of the participant or the absorption, distribution,&#xD;
             metabolism or excretion of the investigational product.&#xD;
&#xD;
         10. Clinically relevant findings in ECG or significant thromboembolic events in medical&#xD;
             history.&#xD;
&#xD;
         11. Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic&#xD;
             therapy in the previous 5 years, and/or uncontrolled diabetes (HbA1c ≥ 7.0).&#xD;
&#xD;
         12. Any known chronic or active neurologic disorder, including seizures and epilepsy,&#xD;
             excluding a single febrile seizure as a child.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marylyn M Addo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marylyn M Addo, MD</last_name>
    <phone>+49 407410</phone>
    <phone_ext>0</phone_ext>
    <email>m.addo@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>CTC North</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marylyn M Addo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anahita Fathi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anastasia Kelidou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MVA</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

